Does rosemary oil work for hair growth?

One 2015 trial is behind almost every claim you have seen. The article reads it properly — what it found, and the four limitations that mean it cannot carry the weight placed on it.

What are the limitations of that study?

No placebo arm, a 2% minoxidil comparator rather than 5%, small and single-site and short, and no certainty about the composition of the oil used.

Is rosemary oil worth using at all?

The proposed mechanisms — vasodilation and quieting perifollicular inflammation — are plausible. Treat it as a reasonable adjunct, not as an equivalent to a proven drug.

Does Rosemary Oil Actually Work for Hair Growth? A Physician Reads the Evidence

2026年8月17日

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.

You saw the video. A bottle of rosemary oil, a scalp massage, a split-screen before-and-after, and a caption telling you that a $9 bottle from the grocery aisle works “as well as minoxidil.” Maybe you have already bought it. Maybe it is sitting on your bathroom counter right now, half-used, and you are wondering whether the tingling and the faint itch at your hairline are signs it is working or signs you are irritating your scalp.

I understand exactly why rosemary oil went viral. It is cheap, it is natural, it smells like something you would want on your head, and — unlike most things that go viral in the hair-loss world — there is a real published clinical trial behind it. That trial is not a myth. It was peer-reviewed, and it deserves to be read honestly.

Honestly, though, means reading all of it: the design, the sample size, the missing placebo arm, and the gap between “a botanical showed a signal in one small study” and “this is a finished product that belongs on your scalp.” As a physician who has spent nearly two decades formulating topicals for hair, I spend much of my professional life in exactly that gap.

My verdict, stated up front so you can hold me to it: rosemary oil is genuinely promising, meaningfully under-proven, and not harmless at the concentrations most people are using. All three are true at once.

The Study Everyone Is Citing: Panahi et al., 2015

The trial that launched a thousand TikToks is Panahi and colleagues, published in Skinmed in 2015. It is worth knowing what it actually did.

Investigators randomized 100 patients with androgenetic alopecia — men and women — to one of two arms: rosemary oil applied to the scalp, or 2% minoxidil solution. Both groups applied their assigned treatment twice daily for six months. Outcomes were assessed by standardized photography and microphotographic hair counts at baseline, three months, and six months (Panahi et al., 2015).

The headline finding: at six months, both groups showed a significant increase in hair count compared with their own baseline, and the difference between the two groups was not statistically significant. The rosemary group also reported less scalp itching than the minoxidil group at the six-month mark.

That is a real, published, randomized result, and I do not want to wave it away. In a field littered with supplement marketing built on nothing but testimonials, having an actual randomized comparative trial puts rosemary oil ahead of ninety percent of what gets sold as a hair remedy.

Now let me tell you why I do not consider the question settled.

What That Trial Cannot Tell You: Four Real Limitations

1. There was no placebo arm

This is the single most important limitation, and it is the one almost never mentioned in the social media version of the story.

The trial compared rosemary oil to minoxidil. It did not compare either to an inert vehicle — a carrier oil alone, or a plain lotion. That matters enormously, because both groups improved from baseline, and without a placebo arm there is no way to know how much of that improvement came from the actives at all.

Consider what every participant did twice a day for six months: they parted their hair, touched their scalp, massaged a liquid into it, and paid close attention to their hairline. Mechanical scalp massage alone has plausible effects on local perfusion. Add the well-documented behavior of androgenetic alopecia itself — it fluctuates seasonally, and enrolled patients frequently improve somewhat simply by being observed. When two active arms both improve and neither is compared to nothing, the honest conclusion is “these two treatments performed similarly,” not “this treatment works.”

2. The comparator was 2% minoxidil, not 5%

The trial used 2% minoxidil. For men with pattern loss, 5% is the concentration with the strongest efficacy data — in the pivotal comparative trial, 5% topical minoxidil produced significantly greater hair count improvement than 2% at 48 weeks (Olsen et al., 2002). Matching a weaker comparator is a lower bar than the headline implies.

3. Small, single-site, and short

Fifty patients per arm is pilot scale, conducted at a single site, and six months is the absolute minimum window for evaluating any hair intervention — the human hair cycle does not move faster than that. Small single-site trials are where hypotheses are generated, not confirmed, and to my knowledge this one has not been replicated at scale by an independent group.

4. Nobody knows what was in the bottle

This is the limitation that matters most for you, personally, standing in a store aisle.

“Rosemary oil” is not a standardized pharmaceutical. It is a plant distillate whose chemistry varies dramatically by chemotype, growing region, harvest timing, distillation method, and storage. The constituents most often proposed as the actives vary several-fold between commercial samples. The oil used in a research setting and the bottle you bought online may share a name and very little else.

So even taking the trial at face value, it does not tell you that your rosemary oil, at your dilution, will do anything. That is the difference between an ingredient with a documented lab signal and a formulated product with a known, reproducible composition.

The Proposed Mechanisms: What Rosemary Might Actually Be Doing

Rosemary’s biological plausibility is genuinely decent. There are three mechanisms most often proposed, and it is worth being precise about the evidence level behind each.

Circulatory: vasodilation and follicular perfusion

Rosemary oil constituents, particularly 1,8-cineole and camphor, have documented vasodilatory and rubefacient properties — they increase local blood flow when applied to skin, which is why they produce the warm tingling you feel. That is the same broad territory minoxidil occupies, though by entirely different pharmacology: minoxidil’s active metabolite opens ATP-sensitive potassium channels and relaxes vascular smooth muscle around the follicle (Messenger & Rundegren, 2004).

Better perfusion of the dermal papilla is a reasonable thing to want; chronically underperfused follicles produce thinner shafts. But “increases local blood flow transiently” is a long way from “reverses miniaturization,” and rubefaction alone has never been shown to durably change hair density.

Anti-inflammatory: quieting the perifollicular environment

Carnosic acid and rosmarinic acid are well-characterized antioxidants with documented anti-inflammatory activity in laboratory models. This matters more than most people appreciate, because perifollicular micro-inflammation is now widely recognized as a co-factor in androgenetic miniaturization — contributing to the fibrotic changes that eventually make loss irreversible. Reducing scalp inflammation is a legitimate target. It is also one that many ingredients address, and rosemary has no established superiority over better-characterized anti-inflammatory actives.

Possible 5-alpha-reductase interaction

The most interesting and least established mechanism. Murata and colleagues reported in Phytotherapy Research that a rosemary leaf extract promoted hair regrowth in testosterone-treated mice and demonstrated 5α-reductase inhibitory activity in vitro, attributing the effect substantially to 12-methoxycarnosic acid, a carnosic acid derivative (Murata et al., 2013).

I want to be careful here, because this is the mechanism most often overstated online. That study used a leaf extract, not the essential oil, in mice and cell-free assays. Rodent hair-growth models are notoriously generous — many things regrow hair on a shaved mouse that do nothing on a human scalp. And 5α-reductase inhibition demonstrated in a test tube tells you a molecule can interact with the enzyme, not that it reaches the enzyme at a meaningful concentration when you rub diluted oil on your head. This is what I mean by “studied in the lab for”: a real documented laboratory interaction that is a reason for interest, not a claim about outcomes in you.

The Gap Between “A Study Exists” and “This Is a Product”

Here is the part of this conversation I care about most, because it applies far beyond rosemary.

A published finding about an ingredient tells you almost nothing about the bottle in your hand. Between a promising botanical and a formulation that reliably does something, a formulator has to solve at least five problems:

Standardization. Without assay-verified raw material, “contains rosemary” is a marketing statement, not a dose.

Stability. Carnosic acid oxidizes readily. An antioxidant, by definition, sacrifices itself — and it does so in the bottle as happily as on your scalp. Without appropriate antioxidant systems, opaque packaging, and validated shelf-life testing, the constituent you paid for degrades before it reaches you.

Penetration. The scalp’s stratum corneum is a genuine barrier, and follicular openings are only a small fraction of surface area. Whether an active reaches the dermal papilla depends on the vehicle far more than on the active. Essential oil in a random carrier oil is not a delivery system; it is a mixture.

Irritation ceiling and manufacturing control. There is always a concentration that would work better and one that damages skin; formulation is the discipline of finding the window between them, and undiluted essential oil is past the ceiling. Batch-to-batch consistency is the point of manufacturing under GMP conditions — which is why MD® products are made in FDA-registered, GMP-compliant facilities in the USA. Facility registration speaks to the reliability of what is in the bottle; it is not product approval by any agency.

None of this is snobbery about DIY. It is an accounting of why an ingredient with a plausible mechanism and a small trial behind it is a starting point for a formulator, not a finished answer for a patient.

Safety: Rosemary Oil Is Not Automatically Gentle

“Natural” is a marketing category, not a safety classification. Essential oils are, by construction, the most chemically concentrated fraction of a plant — and they behave accordingly.

Never apply undiluted

This is the single most important practical point here. Neat (undiluted) essential oil on the scalp is a well-recognized cause of irritant contact dermatitis, burning, and in some individuals sensitization. Standard dilution guidance for leave-on scalp application is 1–3% essential oil in a carrier, and I would not exceed the low end of that on already-irritated skin. Practically, that is a few drops per tablespoon of carrier — not a dropperful applied directly. Jojoba, which is structurally similar to human sebum, and fractionated coconut oil are reasonable carriers; heavier occlusive oils can worsen seborrheic dermatitis, a common and frequently missed co-condition in thinning hair.

Sensitization is real and it is cumulative

Contact allergy to essential oil constituents is well documented in the dermatology literature, and the risk rises with concentration, frequency, and oxidized product (de Groot & Schmidt, 2016). Oxidized terpenes are considerably more sensitizing than fresh ones — meaning that bottle that has been open on your counter for a year is, dermatologically, riskier than a new one. Once you become sensitized to a fragrance constituent, you tend to stay sensitized, and cross-reactivity with related botanicals is common. That is a permanent cost for an unproven benefit, and it is why I ask patients to patch test on the inner forearm for 48 hours before any new botanical goes on the scalp.

There is a clinical irony here worth naming: chronic scalp irritation is itself a poor environment for follicles, driving exactly the perifollicular inflammation that contributes to miniaturization. A person who irritates their scalp for six months chasing an anti-inflammatory benefit can end up net negative.

Who should be more cautious

People with active seborrheic dermatitis or psoriasis on the scalp, anyone with a known fragrance or Lamiaceae-family allergy, and anyone with broken or freshly microneedled skin — where absorption is dramatically increased — should not be applying essential oils without a clinician’s input. Rosemary oil in particular has traditional cautions in pregnancy; the data are thin in either direction, and “thin data during pregnancy” is a reason for restraint, not experimentation. If you are pregnant or nursing, ask your obstetrician before adding any botanical topical.

So Should You Use It? My Actual Clinical Answer

If you want to use rosemary oil, properly diluted, as an adjunct — I am not going to talk you out of it. It is inexpensive, it has a genuine if imperfect trial behind it, and the scalp massage it encourages is probably not doing harm. Patch test first, keep it at 1–3% in a carrier, buy small bottles and replace them often, and stop at the first sign of redness, itch, or flaking.

What I will push back on is treating it as your strategy. Three reasons:

It is a single-mechanism guess at a multi-mechanism problem. Pattern hair loss involves androgen-driven miniaturization, perifollicular inflammation, microcirculatory decline, and — in the majority of women I see — a nutritional or hormonal driver underneath all of it. One botanical, at unknown concentration, does not address that architecture.

It substitutes for diagnosis. The most valuable thing in this article is not a product recommendation. It is this: get labs. Serum ferritin (target above 70 ng/mL for hair purposes, well above the lab-normal cutoff — Trost et al., 2006), a full thyroid panel, vitamin D, and zinc. I have watched people spend two years on essential oils while an untreated thyroid quietly thinned their hair.

Six months of the wrong thing is six months. The follicle has a reversibility window, and once perifollicular fibrosis is established the opportunity narrows. Time spent on an unproven single agent is not free.

The Bottom Line

Rosemary oil sits in an unusual, slightly uncomfortable place: it is one of the few viral hair remedies with an actual randomized trial behind it, and that trial is too small, too short, and too structurally limited to prove what it is being used to claim. Promising is the honest word. Proven is not. It is also not the harmless folk remedy it is marketed as — undiluted essential oil on a scalp is a genuine irritant and a genuine sensitizer, and an inflamed scalp works against the very follicles you are trying to save.

The more useful reframe: rosemary’s plausible mechanisms — improved local perfusion, reduced perifollicular inflammation, possible enzyme interaction — are worth pursuing in a standardized, stability-tested, penetration-designed formulation rather than in a variable plant distillate you dilute by eyeball. The mechanism is the good idea. The bottle in the grocery aisle is not the delivery of it.

Dr. Susan Lin’s Clinical Perspective

“I get asked about rosemary oil more than almost anything else, and my answer disappoints both camps. The Panahi trial is real and I refuse to dismiss it — but it had no placebo arm, and in a field where scalp massage, seasonal variation, and enrollment effects all move hair counts, the absence of a vehicle control is not a technicality. It is the whole question. What frustrates me clinically is not that patients try rosemary oil; it is what they skip while they try it. I have seen women apply it faithfully for a year with a ferritin of 18 and an untreated thyroid. The oil was never the problem — the missing workup was. And I will say the unpopular part plainly: undiluted essential oil on a scalp is an irritant, and an irritated scalp is an inflamed follicular environment. That is the opposite of what we are trying to build.”

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: Rubefaction Versus Regrowth — Why Tingling Is Not Evidence

The sensation rosemary oil produces on the scalp — warmth, tingling, a mild flush — is called rubefaction, and it comes largely from 1,8-cineole and camphor acting on cutaneous sensory receptors and superficial vasculature. It is real, it is immediate, and it is almost universally misread as proof of activity. It is not.

Rubefaction is a superficial dermal phenomenon lasting minutes to hours. Hair follicle regrowth is a deep dermal, months-long process governed by the anagen–catagen–telogen cycle and controlled at the dermal papilla. Transient superficial vasodilation does not reliably reach or reprogram that compartment. Compare the pharmacology: minoxidil’s active metabolite opens ATP-sensitive potassium channels and, more importantly, shortens telogen and extends anagen — an effect on cycle timing, not merely on blood flow (Messenger & Rundegren, 2004). The circulatory component is arguably the least important part of how minoxidil works.

Rosemary’s more interesting mechanism is the quieter one: carnosic acid’s documented antioxidant and anti-inflammatory activity, and the leaf extract’s laboratory-studied interaction with 5α-reductase, attributed to 12-methoxycarnosic acid (Murata et al., 2013). Those act on the actual drivers of miniaturization. Neither produces any sensation at all. In topical hair science, what you feel and what is working are frequently unrelated — and a product that stings is not thereby a product that works.

MD HAIR Product Recommendation

MD® Follicle Energizer — Hair Density Scalp Serum

If what attracted you to rosemary oil was the idea of a drug-free topical that supports the follicle’s local environment, the MD® Follicle Energizer is what that idea looks like once it has been through formulation. It is a Biotinoyl Tripeptide-1 serum designed for the hairline, crown, and part line — the zones where thinning is visible first — at a defined peptide concentration rather than an eyeballed dilution. The precision brush applicator puts it on scalp rather than on hair, which is where topicals either work or do not. The difference from an essential oil is not philosophical, it is practical: standardized raw material, a vehicle designed for penetration, and batch-to-batch manufacturing control in FDA-registered, GMP-compliant facilities in the USA.

In a 119-day (17-week) open-label study conducted by Spincontrol North America on the two-step topical serum system (n=24, no placebo arm, outcomes self-reported by questionnaire), 71% of participants agreed their hair growth had improved. The report itself cautions that the overall satisfaction rate was “not significantly validated.” Individual results vary.

Because pattern thinning also has an internal, androgen-driven component, the internal arm of the MD HAIR routine is MD Nutri Hair™, one capsule daily. Its key botanical is lilac stem-cell extract standardized for verbascoside, a plant phenol which in controlled laboratory studies on human dermal papilla cells — the cells at the base of the follicle — induced cell proliferation, prevented testosterone-induced cell death, and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α (Wisuitiprot et al., 2022). These are cell studies, not human trials, and the authors state that clinical study is still needed.

Genuine MD HAIR and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. Products purchased elsewhere cannot be authenticated by us.

References

Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. (2015). Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed, 13(1), 15–21. PubMed
Murata K, Noguchi K, Kondo M, et al. (2013). Promotion of hair growth by Rosmarinus officinalis leaf extract. Phytotherapy Research, 27(2), 212–217. PubMed
Messenger AG, Rundegren J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186–194. PubMed
Olsen EA, et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377–385. PubMed
de Groot AC, Schmidt E. (2016). Essential oils, part IV: contact allergy. Dermatitis, 27(4), 170–175. PubMed
Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. Journal of the American Academy of Dermatology, 54(5), 824–844. PubMed
Wisuitiprot V, et al. (2022). Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. Scientific Reports, 12, 1491. PubMed

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR, a line of drug-free, clinically informed hair products by La Cañada Ventures, Inc., physician-formulated since 2008. MD HAIR topical products are cosmetics; they are not intended to diagnose, treat, cure, or prevent any disease. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Manufactured in FDA-registered, GMP-compliant facilities in the USA; facility registration is not product approval by the FDA. This article is for educational purposes and does not constitute medical advice. Do not start, stop, or change any medication without consulting your own physician. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.